Shareholders Foundation, Inc.

Synageva Biopharma Corp (NASDAQ:GEVA) Investor Investigation of Buyout by Alexion Pharmaceuticals, Inc

An investigation on behalf of investors of Synageva Biopharma Corp (NASDAQ:GEVA) in connection with the proposed takeover was announced and NASDAQ:GEVA stockholders should contact the Shareholders Foundation.

 

San Diego, CA -- (SBWIRE) -- 05/13/2015 -- An investigation on behalf of investors, who currently hold shares of Synageva Biopharma Corp (NASDAQ:GEVA), was announced concerning whether the takeover of Synageva Biopharma Corp by Alexion Pharmaceuticals, Inc for a value of approximately $230.00 per share is unfair to NASDAQ:GEVA stockholders.

Investors who purchased shares of Synageva Biopharma Corp (NASDAQ:GEVA) and currently hold any of those NASDAQ:GEVA shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of Synageva Biopharma Corp breached their fiduciary duties owed to NASDAQ:GEVA investors in connection with the proposed acquisition.

On May 6, 2015, Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Synageva BioPharma Corp. (Nasdaq:GEVA) announced that they have entered into an agreement pursuant to which Alexion Pharmaceuticals, Inc will acquire Synageva Biopharma Corp (NASDAQ:GEVA) for a consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015.

However, given that in connection with the transaction, certain Synageva Biopharma Corp shareholders, including affiliates of Baker Brothers Investments, have already entered into voting and support agreements with Alexion covering approximately 33.5% of Synageva Biopharma Corp's outstanding shares, the investigation concerns whether the offer is unfair to NASDAQ:GEVA stockholders. More specifically, the investigation concerns whether the Synageva Biopharma Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On May 11, 2015, shares of Synageva Biopharma Corp (NASDAQ:GEVA) closed at $212.80per share.

Those who are current investors in Synageva Biopharma Corp (NASDAQ:GEVA) shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com